SB-1100: An Act to Clarify the Requirements for Accessing Nonformulary Drugs and Drugs Used to Treat Serious Mental Illness
Sponsored by: Sen. Donna Bailey
Received By The Secretary Of The Senate On March 14, 2025 And Referred To The Committee On Health Coverage, Insurance And Financial Services Pursuant To Joint Rule 308.2 on 03/14/2025
SB-1018: An Act to Protect Health Care for Rural and Underserved Areas by Prohibiting Discrimination by Participants in a Federal Drug Discount Program
Sponsored by: Sen. Matthea Larsen Daughtry
Received By The Secretary Of The Senate On March 12, 2025 And Referred To The Committee On Health Coverage, Insurance And Financial Services Pursuant To Joint Rule 308.2 on 03/12/2025
You have voted SB-1018: An Act to Protect Health Care for Rural and Underserved Areas by Prohibiting Discrimination by Participants in a Federal Drug Discount Program.
SB-890: An Act to Permit the Dispensing of Ivermectin Pursuant to a Standing Order upon Request for COVID-19, Flu and Cancer Patients
Sponsored by: Sen. Jeffrey Timberlake
Committee On Health Coverage, Insurance And Financial Services Suggested And Ordered Printed Reference To The Committee On Health Coverage, Insurance And Financial Services Ordered Sent Down Forthwith For Concurrence on 03/04/2025
SB-697: An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing
Sponsored by: Sen. Donna Bailey
Received By The Secretary Of The Senate On February 20, 2025 And Referred To The Committee On Health Coverage, Insurance And Financial Services Pursuant To Joint Rule 308.2 on 02/20/2025
You have voted SB-697: An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing.
HB-538: An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Sponsored by: Rep. Ryan Fecteau
Committee On Health Coverage, Insurance And Financial Services Suggested And Ordered Printed. on 02/11/2025
You have voted HB-538: An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives.
Relating To Prescription Drugs. [SB-1509]
Requires the Legislative Reference Bureau to conduct a study on best practices for the regulation of pharmacy benefit managers and reduction in prescription drug costs for health insurance plan beneficiaries. Requires a report to the Legislature. Effective 12/31/2050. (HD1)
SB-1509: Relating To Prescription Drugs.
Sponsored by: Sen. Ronald Kouchi
Reported From Hlt (stand. Com. Rep. No. 1233) As Amended In Hd 1, Recommending Passage On Second Reading And Referral To Cpc. on 03/14/2025
Relating To Health. [HB-712]
Prohibits drug manufacturers from denying, restricting, or prohibiting the acquisition, shipping, or delivery of a 340B drug to pharmacies contracted with 340B covered entities under the federal 340B Drug Pricing Program. Authorizes the 340B covered entity and Attorney General to bring a civil action for enforcement. Specifies a four-year limitations period for bringing an action. Effective 7/1/3000. (HD2)
HB-712: Relating To Health.
Sponsored by: Rep. Gregg Takayama
The Committee(s) On Hhs/cpn Has Scheduled A Public Hearing On 03-19-25 8:30am; Conference Room 229 & Videoconference. on 03/13/2025
Relating To Health. [SB-480]
Prohibits drug manufacturers and wholesale distributors from restricting or denying access for pharmacies contracted with 340B covered entities to purchase 340B drugs at a discounted price under the federal 340B Drug Pricing Program. Imposes civil penalties for engaging in unfair or deceptive acts or practices in the conduct of any trade or commerce.
SB-480: Relating To Health.
Sponsored by: Sen. Joy San Buenaventura
The Committee On Hhs Deferred The Measure. on 02/10/2025
Relating To Prescription Drugs. [HB-216]
Establishes requirements for the clinical review criteria and clinical practical guidelines used to establish step therapy protocols. Provides a process for a patient to request an exception to using step therapy protocols. Establishes insurance coverage requirements relating to the use of step therapy protocols and standards to appeal an adverse step therapy exception determination.
HB-216: Relating To Prescription Drugs.
Sponsored by: Rep. Gregg Takayama
Referred To Hlt, Cpc, Fin, Referral Sheet 1 on 01/21/2025
Relating To Prescription Drugs. [SB-226]
Establishes requirements for the clinical review criteria and clinical practical guidelines used to establish step therapy protocols. Provides a process for a patient to request an exception to using step therapy protocols. Establishes insurance coverage requirements relating to the use of step therapy protocols and standards to appeal an adverse step therapy exception determination.
SB-226: Relating To Prescription Drugs.
Sponsored by: Sen. Lynn Decoite
Referred To Hhs, Cpn. on 01/17/2025
HB-180: An Act Regarding the Interactions of Pharmacy Benefits Managers and So-called 340B Entities and Reimbursements by Pharmacy Benefits Managers to Pharmacies
Sponsored by: Rep. Kristi Mathieson
Committee On Health Coverage, Insurance And Financial Services Suggested And Ordered Printed. on 01/14/2025
You have voted HB-180: An Act Regarding the Interactions of Pharmacy Benefits Managers and So-called 340B Entities and Reimbursements by Pharmacy Benefits Managers to Pharmacies.
You have voted SB-2282: An Act to Provide Greater Transparency About the Cost of Insulin and to Promote the Availability of Low-cost Insulin in the State.